333
Views
10
CrossRef citations to date
0
Altmetric
Review

Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders

ORCID Icon, , , &
Pages 923-944 | Received 07 Jun 2021, Accepted 19 Jul 2021, Published online: 18 Aug 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Andreas A. Argyriou, Elisa Mantovani, Dimos-Dimitrios Mitsikostas, Michail Vikelis & Stefano Tamburin. (2022) A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. Expert Review of Neurotherapeutics 22:6, pages 469-488.
Read now

Articles from other publishers (9)

Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos & Michail Vikelis. (2023) Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry. European Journal of Neurology 30:5, pages 1435-1442.
Crossref
Soonwook Kwon, Mi Ji Lee & Manho Kim. (2023) Epicranial headache part 1: Primary stabbing headache. Cephalalgia 43:2, pages 033310242211469.
Crossref
Emmanouil V. Dermitzakis, Aikaterini Kouroudi, Andreas A. Argyriou, Konstantinos C. Spingos, Konstantinos Bilias & Michail Vikelis. (2022) Results of a Web-Based Survey on 2105 Greek Migraine Patients—Second Part: Efficacy of Acute and Prophylactic Migraine Treatments and Corresponding Patients’ Reported Satisfaction. Medicina 59:1, pages 31.
Crossref
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou & Michail Vikelis. (2022) OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. Toxins 14:12, pages 847.
Crossref
Parisa Gazerani. (2022) How Does Botulinum Toxin Inhibit Itch?. Toxins 14:10, pages 701.
Crossref
Emmanouil V. Dermitzakis, Michail Vikelis, George S. Vlachos & Andreas A. Argyriou. (2022) Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis. Toxins 14:5, pages 296.
Crossref
Negar Shaterian, Negin Shaterian, Aref Ghanaatpisheh, Farnaz Abbasi, Sara Daniali, Maryam Jalali Jahromi, Mohammad Sadegh Sanie & Amir Abdoli. (2022) Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain Research and Management 2022, pages 1-15.
Crossref
亚辉 秦. (2022) Advances in Application of Botulinum Toxin Type A in Neurology. Advances in Clinical Medicine 12:03, pages 1679-1685.
Crossref
Yuri Chaves-Martins. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology 532 547 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.